1-6 of 6
Kellie J. Ryan
Close
Sort by
Journal Articles

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4156–4158.
https://doi.org/10.1182/blood-2022-167213
Published: 2022
Journal Articles

Shift in First-Line Therapies for United States Veterans Health Administration (VHA) Patients with Chronic Lymphocytic Leukemia (CLL) from 2014 to 2021

Kana Tai Lucero, Christopher R. Frei, Kellie J. Ryan, Obiageri O. Obodozie-Ofoegbu, Amanda M. Moore, Chengwen Teng, Xavier Jones, Zohra Nooruddin
Journal: Blood
Blood (2022) 140 (Supplement 1): 9915–9916.
https://doi.org/10.1182/blood-2022-163797
Published: 2022
Journal Articles

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lindsey E. Roeker, Yi Han, Kellie J. Ryan, Anna Teschemaker, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 7025–7027.
https://doi.org/10.1182/blood-2022-163534
Published: 2022
Journal Articles

Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

Michael Wallington, Xavier Guillaume, Emily Mulvihill, Graceanne R Wayser, Vandana Kaul, Claire Graziani-Taugeron, Mina Shahkarami, Kellie J. Ryan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10810–10811.
https://doi.org/10.1182/blood-2022-165766
Published: 2022
Journal Articles

Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study

Kana Tai Lucero, Obiageri O. Obodozie-Ofoegbu, Zohra Nooruddin, Alyssa Castillo, Amanda M. Moore, Kellie J. Ryan, Xavier Jones, Christopher R. Frei
Journal: Blood
Blood (2021) 138 (Supplement 1): 340.
https://doi.org/10.1182/blood-2021-146860
Published: 2021
Journal Articles

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Hetalkumari Patel, Svea K. Wahlstrom, Maral DerSarkissian, Colin Kunzweiler, Felicia Castriota, Rose Chang, Hoi Ching Cheung, Yuqian Gu, Helen Guo, Mei Sheng Duh, Kellie J. Ryan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2999.
https://doi.org/10.1182/blood-2021-147449
Published: 2021